We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.00 | 17.50 | 18.50 | 18.00 | 18.00 | 18.00 | 66,018 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.34 | 16.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/3/2017 08:38 | Here come the cavalry! :) | judijudi | |
22/3/2017 08:34 | Spike that's about 1M how much value do you think the market has been giving Skin B, couple of million tops. | john henry | |
22/3/2017 08:27 | They could be selling because whereas we have had expectations of Skin being an 'earner' sooner rather than later - fact is we now know they don't have the funds to do that, and we now know that their 'leading product' will not be commercialised until sometime next year. And we know that the value (sp) of OPTI will in the near term take a hit (as %60 of skin value will be taken out). Best wishes - Mike | spike_1 | |
22/3/2017 08:23 | To be honest i think a little pullback to the 80p mark was to be expected before we start to move back up,lots of news could hit at any time ;)) | scotty1 | |
22/3/2017 08:18 | Surprised to see the selling given yesterday's RNS. It wasn't what I expected to see here early doors. Thought we'd hold 82p Bid at least! You can always trust AIM for the unexpected to occur! | bdog51 | |
22/3/2017 08:17 | scotty, Their loss and lets hope they live to regret it as a bad decision | judijudi | |
22/3/2017 08:17 | May be SV. | rafboy | |
22/3/2017 08:16 | Must admit to being a little disappointed with the initial reaction today. Yesterdays news pretty much wiped out. A retest of the break looks likely. | john henry | |
22/3/2017 08:14 | jj you are always going to get sellers mate and they probably think they can sell and buy back cheaper,not a risk i would take at this point in time, plus i don't think the market fully understands the significance of y'days RNS yet,but i'm sure they will soon ;) | scotty1 | |
22/3/2017 08:14 | Looks like yet again we ain't gonna hold 80p Fools | judijudi | |
22/3/2017 08:12 | Tax planning perhaps Raf? | semper vigilans | |
22/3/2017 08:11 | Amazing people selling, hope they have a good reason. | rafboy | |
22/3/2017 08:05 | JJ peeps that are not interested in the fundamentals. 43 K dumped already. obviously not interested in being given shares in Skin Th. The record date has not being given yet, todays sellers are unlikely to receive shares. | john henry | |
22/3/2017 08:03 | I cannot understand why anybody would sell now? | judijudi | |
22/3/2017 08:02 | Shazbo buy T20 sir..... | bernieboy | |
22/3/2017 07:58 | People, stop buying and stop talking this share up! Can we just try to keep the lid on this for a bit longer :) We're less than three weeks away from the new tax year and can shelter another 20k of Opti from the taxman. Personally I'm due a decent bonus last day of March and it was all earmarked for Opti, but I guess I'm just being greedy aren't I? | shazbo | |
22/3/2017 07:47 | I loved the fact that the RNS came out at lunchtime yesterday. Virtually every morning for over two years I have checked at 7am only to be disappointed so many times. Now that one came during the day that 7am deadline has pleasantly disappeared...... | bernieboy | |
22/3/2017 07:11 | Good find vivgav. This listing certainly seems to be getting lots of coverage - all helping to raise their profile not only with investors, but also major players who they would look to partner with. The Life Sciences team at Instinctif Partners are looking after Skin's float & financial PR: The 'Market opportunity of skin microbiome' and 'SkinBioTherapeutics "The vast majority of academic research and investment (over $1 billion since 2014) has been into the gut microbiome and treatments for local conditions to the gut. Less than 5% of published research has been on the skin microbiome. The management of SkinBioTherapeutics believes there is significant early mover advantage to creating treatment utilising the microbiome and extracts from probiotic bacteria found in the gut and creating a treatment for the skin." And there's that term again: EARLY MOVER ADVANTAGE. The party is only just starting here people... | parob | |
21/3/2017 23:46 | Ah, senior moment! You must be talking of michaelmouse. I haven't ventured to the other side today. Fish in a barrel...the mouse knows no shame. Let me guess...his argument remains OPTI market cap being too high, dilutive placing a hoy, cold winter 40p soon, then 8p, demerger is a cash call by another name, but I wish you all well ;-) All examples of the void in his knowledge of OPTI and the market mechanics. I don't waste my time discussing OPTI with him. I much rather demonstrate his errors and lies in the hope he does not put off potential investors with his lies and misinformation and of course, poor investment choices and of course, the two frauds and other than uses accounting smoke and mirrors to create the illusion of a growth company. I bet he still thinks TRAKM8 is worth £20! I at least got my 60p target right for TRAKM8. He didn't have the courtesy to thank me either ;-) | elrico | |
21/3/2017 23:19 | Owen - Sorry pal, I don't follow? Nose for detail? Whom do you speak of? | elrico | |
21/3/2017 23:14 | Elrico, top of the league to-day indeed - and, paradoxically, the lengthiest submissions emanating from a non-investor with little else to do than nit-pick. What a pity that his nose for detail couldn't convert into something positive for himself and in turn for us. | owenmo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions